Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase I study on bruceantin administered on a weekly schedule

J Liesmann, R J Belt, C D Haas

    Cancer Treatment Reports
    |September 1, 1981
    PubMed
    Summary

    Bruceantin treatment for advanced solid tumors showed dose-limiting nausea and vomiting, particularly in patients with liver issues. The recommended Phase II dose is 5 mg/m2 weekly, with adjustments for hepatic metastases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.

    Annals of oncology : official journal of the European Society for Medical Oncology·2009
    Same author

    Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study.

    Cancer·2000
    Same author

    Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma.

    Annals of oncology : official journal of the European Society for Medical Oncology·1994
    Same author

    Phase II trial of piroxantrone for advanced or metastatic soft tissue sarcomas. A Southwest Oncology Group study.

    Investigational new drugs·1993
    Same author

    Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinoma.

    Cancer·1992
    Same author

    Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·1992

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Advanced solid tumors represent a significant challenge in cancer treatment.
    • Bruceantin is an investigational agent explored for its anti-cancer properties.

    Purpose of the Study:

    • To evaluate the safety and tolerability of bruceantin in adult patients with advanced solid tumors.
    • To determine the dose-limiting toxic effects and establish a recommended dose for Phase II studies.

    Main Methods:

    • A Phase I clinical trial involving fifteen adult patients with advanced solid tumors.
    • Bruceantin was administered intravenously at doses ranging from 1.6-6.0 mg/m2 weekly for 4 weeks, followed by a 2-week rest period.
    • Adverse events and toxicities were closely monitored.

    Main Results:

    • Nausea and vomiting were identified as the dose-limiting toxic effects, exacerbated by hepatic metastases or liver function abnormalities.
    • Other observed toxicities included fever, chills, malaise, alopecia, hypotension, thrombocytosis, and leukocytosis.
    • Hematologic toxicity was minimal.

    Conclusions:

    • The recommended starting dose for Phase II studies is 5 mg/m2/week X 4, every 6 weeks.
    • A reduced dose of 3 mg/m2 is recommended for patients with hepatic metastases due to increased risk of severe nausea and vomiting.
    • Bruceantin demonstrates a specific toxicity profile that requires careful dose management, especially in patients with pre-existing liver conditions.

    Related Experiment Videos